Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | HINT1 | P49773 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883219 | 0.92 | TAS1R3 (0.62) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL22883221 | 0.92 | KDM4E (0.48) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL25613001 | 0.92 | KDM4E (0.48) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL22034192 | 0.90 | TAS1R3 (0.54) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL29881515 | 0.90 | TAS1R3 (0.54) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL27216192 | 0.90 | TAS1R3 (0.54) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL18490364 | 0.90 | TAS1R3 (0.54) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL25107034 | 0.89 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL29664919 | 0.89 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL29870610 | 0.89 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3573718-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2018138685-A2 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | TAS1R3 556/4885TAS1R1 302/4885KDM4E 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.